China-based glycolipid metabolism specialist Cholesgen (Shanghai) Co. Ltd. has reportedly raised over RMB100 million ($13.8 million) in a Series A financing round led by SDIC. The AstraZeneca-CICC Medical Industry Investment Fund, an existing investor, also participated. The proceeds will fund clinical filings, development of core pipelines, and expansion of the R&D platform and team.
Company Focus
Cholesgen is focused on innovative targets in the cholesterol metabolism pathway with high druggability. The company is developing novel therapies for hyperlipidemia, obesity, diabetes, atherosclerosis, and metabolic-associated steatohepatitis (MASH).
Funding and Future Plans
The funding will accelerate Cholesgen’s efforts to advance its pipeline of metabolic disease treatments. The company plans to leverage the capital to expand its R&D capabilities and bring its innovative drug candidates closer to market.-Fineline Info & Tech
Leave a Reply